FILE 'HOME' ENTERED AT 16:36:35 ON 04 OCT 2002

=> file medline caplus embase biosis uspatful cancerlit
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 16:37:22 ON 04 OCT 2002

FILE 'CAPLUS' ENTERED AT 16:37:22 ON 04 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 16:37:22 ON 04 OCT 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:37:22 ON 04 OCT 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'USPATFULL' ENTERED AT 16:37:22 ON 04 OCT 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CANCERLIT' ENTERED AT 16:37:22 ON 04 OCT 2002

=> s contact (w) blood (w) patient
L1 2 CONTACT (W) BLOOD (W) PATIENT

=> d l1 1- ibib,abs
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L1 ANSWER 1 OF 2 USPATFULL
ACCESSION NUMBER: 2002:243051 USPATFULL
TITLE: Compositions and methods for the therapy and diagnosis
of ovarian cancer
INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132237	A1	20020919
APPLICATION INFO.:	US 2001-867701	A1	20010529 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 25718
AB Compositions and methods for the therapy and diagnosis of cancer,
particularly ovarian cancer, are disclosed. Illustrative compositions
comprise one or more ovarian tumor polypeptides, immunogenic portions
thereof, polynucleotides that encode such polypeptides, antigen
presenting cell that expresses such polypeptides, and T cells that are
specific for cells expressing such polypeptides. The disclosed
compositions are useful, for example, in the diagnosis, prevention
and/or treatment of diseases, particularly ovarian cancer.

L1 ANSWER 2 OF 2 USPATFULL
ACCESSION NUMBER: 2002:242791 USPATFULL
TITLE: Compositions and methods for the therapy and diagnosis
of colon cancer
INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002131971	A1	20020919
APPLICATION INFO.:	US 2001-33528	A1	20011226 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-920300, filed
on 31 Jul 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)
	US 2001-279763P	20010328 (60)
	US 2000-223283P	20000803 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 8083
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

=> s ultrapheresis or apheresis
L2 9899 ULTRAPHERESIS OR APHERESIS

=> s (GM-CSF or M-CSF or erythropoietin or thrombopoetin or G-CSF or SCF) receptor (w) antibody
MISSING OPERATOR SCF) RECEPTOR
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s (GM-CSF or M-CSF or erythropoietin or thrombopoetin or G-CSF or SCF)(w) receptor (w) antibody
L3 47 (GM-CSF OR M-CSF OR ERYTHROPOIETIN OR THROMBOPOETIN OR G-CSF OR SCF)(W) RECEPTOR (W) ANTIBODY

=> s l2 and l3
L4 0 L2 AND L3

=> s (GM-CSF or M-CSF or erythropoietin or thrombopoetin or G-CSF or SCF)(w) receptor
L5 9605 (GM-CSF OR M-CSF OR ERYTHROPOIETIN OR THROMBOPOETIN OR G-CSF OR SCF)(W) RECEPTOR

=> s l2 and l5
L6 21 L2 AND L5

=> duplicate remove l6
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, EMBASE, BIOSIS, USPATFULL, CANCERLIT'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L6
L7 14 DUPLICATE REMOVE L6 (7 DUPLICATES REMOVED)

=> d l7 1- ibib,abs
YOU HAVE REQUESTED DATA FROM 14 ANSWERS - CONTINUE? Y/(N):y

L7 ANSWER 1 OF 14 USPATFULL
ACCESSION NUMBER: 2002:258892
USPATFULL
TITLE: Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood
INVENTOR(S): Ildstad, Suzanne T., Wynewood, PA, UNITED STATES
Zorina, Tatiana D., Aldan, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142462	A1	20021003
APPLICATION INFO.:	US 2002-78328	A1	20020215 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-468686, filed on 21 Dec 1999, ABANDONED Continuation of Ser. No. US 1998-72862, filed on 5 May 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-986511, filed on 8 Dec 1997, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-66821P	19971126 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Licata & Tyrrell P.C., 66 E. Main Street, Marlton, NJ, 08053
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 2027
AB The present invention relates to methods for mobilizing hematopoietic facilitating cells (FC) and hematopoietic stem cells (HSC) into a subject's peripheral blood (PB). In particular, the invention relates to the activation of both FLT3 and granulocyte-colony stimulating factor (G-CSF) receptor to increase the numbers of FC and HSC in the PB of a donor. The donor's blood contains both mobilized FC and HSC, and can be processed and used to repopulate the destroyed lymphohematopoietic system of a recipient. Therefore, PB containing FC and HSC mobilized by the method of the invention is useful as a source of donor cells in bone marrow transplantation for the treatment of a variety of disorders, including cancer, anemia, autoimmunity and immunodeficiency. Alternatively, the donor's hematopoietic tissue, such as bone marrow, can be treated ex vivo to enrich selectively for FC and HSC populations by activating appropriate cell surface receptors.

L7 ANSWER 2 OF 14 USPATFULL
ACCESSION NUMBER: 2002:60683 USPATFULL
TITLE: DENDRITIC CELL STIMULATORY FACTOR
INVENTOR(S): BRASEL, KENNETH, SEATTLE, WA, UNITED STATES
LYMAN, STEWART D., SEATTLE, WA, UNITED STATES
MARASKOVSKY, EUGENE, SEATTLE, AUSTRALIA
MCKENNA, HILARY J, SEATTLE, WA, UNITED STATES
LYNCH, DAVID H., BAINBRIDGE ISLAND, WA, UNITED STATES
MALISZEWSKI, CHARLES R., SEATTLE, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002034517	A1	20020321
APPLICATION INFO.:	US 1999-448378	A1	19991123 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-725540, filed on 3 Oct
1996, ABANDONED Continuation-in-part of Ser. No. US
1995-539142, filed on 4 Oct 1995, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: IMMUNEX CORPORATION, LAW DEPARTMENT, 51 UNIVERSITY
STREET, SEATTLE, WA, 98101
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 804
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Flt3-ligand can be used to generate large numbers of dendritic cells
from hematopoietic progenitor and stem cells. Flt3-ligand can be used to
augment immune responses in vivo, and expand dendritic cells ex vivo.
Such dendritic cells can then be used to present tumor, viral or other
antigens to naive T cells, can be useful as vaccine adjuvants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 14 USPATFULL
ACCESSION NUMBER: 2002:31955 USPATFULL
TITLE: MONOCLONAL ANTIBODIES TO STEM CELL FACTOR RECEPTORS
INVENTOR(S): BROUDY, VIRGINIA C, SEATTLE, WA, UNITED STATES
LIN, NANCY, SEATTLE, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002018775	A1	20020214
APPLICATION INFO.:	US 1999-352466	A1	19990713 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-255193, filed on 7 Jun
1994, GRANTED, Pat. No. US 5922847
Division of Ser. No.
US 1993-11078, filed on 29 Jan 1993, GRANTED, Pat. No.
US 5489516 Continuation of Ser. No. US 1991-681245,
filed on 5 Apr 1991, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER
DRIVE, THOUSAND OAKS, CA, 91320-1799
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 1006
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to monoclonal antibodies specific for a
cell receptor specific for human stem cell factor (hSCF) as well as
pharmaceutical compositions containing such monoclonal antibodies and
uses of such monoclonal antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 14 USPATFULL
ACCESSION NUMBER: 2002:160351 USPATFULL
TITLE: Methods of ex-vivo expansion of hematopoietic cells
using interleukin-3 mutant polypeptides with other
hematopoietic growth factors
INVENTOR(S): Bauer, S. Christopher, 4656 Orchard Rd., New Haven, MO,
United States 63068
Abrams, Mark Allen, 7723 Blackberry Ave., St. Louis,
MO, United States 63130
Braford-Goldberg, Sarah Ruth, 4111 W. Pine #10, St.
Louis, MO, United States 63108
Caparon, Maire Helena, 109 Beechwood Ct., Chesterfield,
MO, United States 63017
Easton, Alan Michael, 2317 Seven Pines Dr. #7, Maryland
Heights, MO, United States 63146
Klein, Barbara Kure, 12917 Topping Estates, St. Louis,
MO, United States 63131
McKearn, John P., 18612 Babler Meadows Dr., Glencoe,
MO, United States 63038
Olins, Peter O., 10625 Goose Haven, Lafayette, CO,
United States 80026
Paik, Kumnan, 636 Illinois Rd., Wilmette, IL, United
States 60091
Thomas, John, 13426 Mason Valley Ct., Town & Country,
MO, United States 63131

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6413509 B1 20020702
APPLICATION INFO.: US 1996-761907 19961209 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 446871
Continuation-in-part of Ser. No. US 1994-193373, filed
on 4 Feb 1994, now patented, Pat. No. US 6153183
Continuation-in-part of Ser. No. US 411795, now
patented, Pat. No. US 5604116 Continuation-in-part of
Ser. No. US 1992-981044, filed on 24 Nov 1992, now
abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kunz, Gary L.
ASSISTANT EXAMINER: Landsman, Robert S.
LEGAL REPRESENTATIVE: Bennett, Dennis A., Bauer, S. Christopher
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 5796
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods of ex-vivo expansion of
hematopoietic cells by culturing hematopoietic cells in a growth medium
comprising a variant of human interleukin-3 (hIL-3), which contains
multiple amino acid substitutions and which may have portions of the
native hIL-3 molecule deleted, and a hematopoietic growth factor. The
present invention also relates to the ex-vivo expansion of hematopoietic
cells for gene therapy. Additionally, the present invention relates to
the use of the expanded hematopoietic cells for treating patients having
a hematopoietic disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:396701 CAPLUS
DOCUMENT NUMBER: 135:10107
TITLE: Antitumor ultrapheresis method and system to
remove cytokine inhibitor in patients
INVENTOR(S): Lentz, M. Rigdon
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037873	A2	20010531	WO 2000-US42090	20001110
WO 2001037873	A3	20020307		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1227843 A2 20020807 EP 2000-992499 20001110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.: US 1999-164695P P 19991110
WO 2000-US42090 W 20001110

AB A method to treat cancer uses ultrapheresis, refined to remove
compds. of less than 120,000 daltons mol. wt., followed by administration
of replacement fluid, to stimulate the patient's immune system to attack
solid tumors. In the preferred embodiment, the patient is ultrapheresed
using a capillary tube ultrafilter having a pore size of 0.02 to 0.05
.mu., with a mol. wt. cutoff of 120,000 daltons, sufficient to filter one
blood vol. The preferred replacement fluid is ultrapheresed normal
plasma. The patient is preferably treated daily for three weeks,
diagnostic tests conducted to verify that there has been shrinkage of the
tumors, then the treatment regime is repeated. The treatment is
preferably combined with an alternative therapy, for example, treatment
with an antiangiogenic compd., one or more cytokines, such as TNF, gamma
interferon, or IL-2, or a procoagulant compd. The treatment increases
endogenous, local levels of cytokines, such as TNF. This provides a basis
for an improved effect when combined with any treatment that enhances
cytokine activity against the tumors, for example, treatments using
alkylating agents, doxorubicin, carboplatinum, cisplatinum, and taxol.
Alternatively, the ultrapheresis treatment can be combined with
local chemotherapy, systemic chemotherapy, and/or radiation.

L7 ANSWER 6 OF 14 USPATFULL
ACCESSION NUMBER: 2000:125097 USPATFULL

TITLE: Combination anti-leukemic therapy by utilizing suramin
and biologic response modifiers
INVENTOR(S): Doukas, Michael A., Lexington, KY, United States
PATENT ASSIGNEE(S): The University of Kentucky Research Foundation,
Lexington, KY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6121320		20000919
APPLICATION INFO.:	US 1998-31037		19980226 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-39260P	19970226 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Goldberg, Jerome D.
LEGAL REPRESENTATIVE: McDermott, Will & Emery
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1173
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating leukemia which includes administering an effective
amount of composition comprising suramin and a biological response
modifier, wherein the suramin and the biological response modifier show
synergistic or additive anti-leukemic activity. A pharmaceutical
composition is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 14 USPATFULL
ACCESSION NUMBER: 1999:78852 USPATFULL
TITLE: Methods of purifying hematopoietic cells using an
antibody to a stem cell factor receptor
INVENTOR(S): Broudy, Virginia C., Seattle, WA, United States
Lin, Nancy, Seattle, WA, United States
PATENT ASSIGNEE(S): Amgen Inc., Thousand Oaks, CA, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5922847		19990713
APPLICATION INFO.:	US 1994-255193		19940607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-11078, filed on 29 Jan
1993, now patented, Pat. No. US 5489516 which is a
continuation of Ser. No. US 1991-681245, filed on 5 Apr
1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Reeves, Julie
LEGAL REPRESENTATIVE: Odre, Steven M., Levy, Ron K., Winter, Robert B.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1079
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to monoclonal antibodies specific for a
cell receptor specific for human stem cell factor (hSCF) as well as
pharmaceutical compositions containing such monoclonal antibodies and
uses of such monoclonal antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 14 USPATFULL
ACCESSION NUMBER: 1999:75767 USPATFULL
TITLE: Monoclonal antibodies to stem cell factor receptors
INVENTOR(S): Broudy, Virginia C., Seattle, WA, United States
Lin, Nancy, Seattle, WA, United States
PATENT ASSIGNEE(S): Board of Regents of the University of Washington,
Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5919911		19990706
APPLICATION INFO.:	US 1995-462638		19950605 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-11078, filed on 29 Jan
1993, now patented, Pat. No. US 5489516 which is a
continuation of Ser. No. US 1991-681245, filed on 5 Apr
1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Huff, Sheela
ASSISTANT EXAMINER: Reeves, Julie E.
LEGAL REPRESENTATIVE: Winter, Robert B., Odre, Steve M., Levy, Ron K.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1057
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to monoclonal antibodies specific for a
cell receptor specific for human stem cell factor (hSCF) as well as
pharmaceutical compositions containing such monoclonal antibodies and
uses of such monoclonal antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 14 USPATFULL
ACCESSION NUMBER: 1999:61124 USPATFULL

TITLE: Method of reconstituting hematopoietic cells using
monoclonal antibodies to the stem cell factor receptor
INVENTOR(S): Broudy, Virginia C., Seattle, WA, United States
Lin, Nancy, Seattle, WA, United States
PATENT ASSIGNEE(S): Board of Regents of the University of Washington,
Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5906938		19990525
APPLICATION INFO.:	US 1995-449139		19950524 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-11078, filed on 29 Jan
1993, now patented, Pat. No. US 5489516 which is a
continuation of Ser. No. US 1991-681245, filed on 5 Apr
1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Huff, Sheela
ASSISTANT EXAMINER: Reeves, Julie E
LEGAL REPRESENTATIVE: Winter, Robert B., Odre, Steve M., Levy, Ron K.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1108
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to monoclonal antibodies specific for a
cell receptor specific for human stem cell factor (hSCF) as well as
pharmaceutical compositions containing such monoclonal antibodies and
uses of such monoclonal antibodies for the isolation and reconstitution
of hematopoietic cells expressing the stem cell factor receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 14 MEDLINE
DUPLICATE 1
ACCESSION NUMBER: 1999445086 MEDLINE
DOCUMENT NUMBER: 99445086 PubMed ID: 10517498
TITLE: Myelopoietin, a chimeric agonist of human interleukin 3 and
granulocyte colony-stimulating factor receptors, mobilizes
CD34+ cells that rapidly engraft lethally x-irradiated
nonhuman primates.
AUTHOR: MacVittie T J; Farese A M; Davis T A; Lind L B; McKearn J P
CORPORATE SOURCE: Greenebaum Cancer Center, Baltimore, MD 21201, USA..
tmacvitt@umaryland.edu
SOURCE: EXPERIMENTAL HEMATOLOGY, (1999 Oct) 27 (10) 1557-68.
Journal code: 0402313. ISSN: 0301-472X.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199910
ENTRY DATE: Entered STN: 20000111
Last Updated on STN: 20000111
Entered Medline: 19991026
AB Myelopoietin (MPO), a multifunctional agonist of interleukin 3 and
granulocyte colony-stimulating factor (G-CSF)
receptors, was evaluated for its ability to mobilize hematopoietic
colony-forming cells (CFC) and CD34+ cells relative to control cytokines
in normal nonhuman primates. Additionally, the engraftment potential of
MPO-mobilized CD34+ cells was assessed in lethally irradiated rhesus
monkeys. Normal rhesus monkeys were administered either MPO (200
microg/kg/day), daniplestim (a high-affinity interleukin 3 receptor
agonist) (100 microg/kg/day), G-CSF (100 microg/kg/day), or daniplestim
coadministered with G-CSF (100 microg/kg/day each), subcutaneously for 10
consecutive days. The mobilization kinetics were characterized by
peripheral blood (PB) complete blood counts, hematopoietic CFC
[granulocyte-macrophage CFC (GM-CFC), megakaryocyte CFC (MK-CFC)], and the
immunophenotype (CD34+ cells) of PB nucleated cells prior to and on day 3
to days 7, 10, 12, and 14, and at intervals up to day 28 following
initiation of cytokine administration. A single large-volume leukapheresis
was conducted on day 5 in an additional cohort (n = 10) of MPO-mobilized
animals. Eight of these animals were transplanted with two doses of CD34+
cells/kg. A maximum 10-fold increase in PB leukocytes (white blood cells)
(from baseline 7.8-12.3 x 10(3)/microL to approximately 90 x 10(3)/microL)
was observed over day 7 to day 10 in the MPO, G-CSF, or daniplestim+G-CSF
cohorts, whereas daniplestim alone stimulated a less than onefold
increase. A sustained, maximal rise in PB-derived GM-CFC/mL was observed
over day 4 to day 10 for the MPO-treated cohort, whereas the
daniplestim+G-CSF, G-CSF alone, and daniplestim alone treated cohorts were
characterized by a mean peak value on days 7, 6, and 18, respectively.
Mean peak values for PB-derived GM-CFC/mL were greater for MPO (5,427/mL)
than for daniplestim+G-CSF (3,534/mL), G-CSF alone (3,437/mL), or
daniplestim alone (155/mL) treated cohorts. Mean peak values for CD34+
cells/mL were noted within day 4 to day 5 of cytokine administration: MPO
(255/microL, day 5), daniplestim+G-CSF (47/microL, day 5), G-CSF

(182/microL, day 4), and daniplestim (96/microL, day 5). Analysis of the
mobilization data as area under the curve indicated that for total CFCs,
GM-CFC, MK-CFC, or CD34+ cells, the MPO-treated areas under the curve were
greater than those for all other experimental cohorts. A single,
large-volume (3.0 x blood volume) leukapheresis at day 5 of MPO
administration (PB: CD34+ cell/microL = 438 +/- 140, CFC/mL = 5,170 +/-
140) resulted in collection of sufficient CD34+ cells (4.31 x 10(6)/kg +/-
1.08) and/or total CFCs (33.8 x 10(4)/kg +/- 8.34) for autologous
transplantation of the lethally irradiated host. The immunoselected CD34+
cells were transfused into autologous recipients (n = 8) at cell doses of
2 x 10(6)/kg (n = 5), and 4 x 10(6)/kg (n = 3) on the day of
apheresis. Successful engraftment occurred with each cell dose.
The data demonstrated that MPO is an effective and efficient mobilizer of
PB progenitor cells and CD34+ cells, such that a single leukapheresis
procedure results in collection of sufficient stem cells for
transplantation and long term engraftment of lethally irradiated hosts.

L7 ANSWER 11 OF 14 USPATFULL
ACCESSION NUMBER: 1998:143911 USPATFULL
TITLE: Hox-induced enhancement of in vivo and in vitro
proliferative capacity and gene therapeutic methods
INVENTOR(S): Largman, Corey, Berkley, CA, United States
Lawrence, Hugh Jeffrey, Lafayette, CA, United States
Humphries, R. Keith, Vancouver, Canada
Sauvageau, Guy, 7390 De Tilly, Montreal, P.O., Canada
H3R 3E3
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland,
CA, United States (U.S. corporation)
Humphries, Keith, Oakland, CA, United States (U.S. individual)
Sauvageau, Guy, Oakland, CA, United States (U.S. individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5837507		19981117
APPLICATION INFO.:	US 1995-557973		19951113 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Saunders, David
ASSISTANT EXAMINER: VanderVegt, F. Pierre
LEGAL REPRESENTATIVE: Bozicevic, KarlBozicevic & Reed LLP
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1431
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Stem cells transduced with HOXB4 exhibit enhanced in vitro and in vivo
ability for self-regeneration and generate higher-numbers of
tranplantable pluripotent hematopoietic stem cells relative to control
and nonmanipulated cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 14 USPATFULL
ACCESSION NUMBER: 1998:57716 USPATFULL
TITLE: Aptamers specific for biomolecules and methods of
making
INVENTOR(S): Griffin, Linda, Atherton, CA, United States
Albrecht, Glenn, Redwood City, CA, United States
Latham, John, Palo Alto, CA, United States
Leung, Lawrence, Hillsborough, CA, United States
Vermaas, Eric, Oakland, CA, United States
Toole, John J., Burlingame, CA, United States
PATENT ASSIGNEE(S): Gilead Sciences, Inc., Foster City, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5756291		19980526
APPLICATION INFO.:	US 1995-484192		19950607 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-934387, filed on 21
Aug 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
LEGAL REPRESENTATIVE: Bosse, Mark L.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 8242
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for identifying oligomer sequences, optionally comprising
modified base, which specifically bind target molecules such as serum
proteins, kinins, eicosanoids and extracellular proteins is described.
The method is used to generate aptamers that bind to serum Factor X,
PDGF, FGF, ICAM, VCAM, E-selectin, thrombin, bradykinin, PGF2 and cell
surface molecules. The technique involves complexation of the target

molecule with a mixture of oligonucleotides containing random sequences and sequences which serve as primer for PCR under conditions wherein a complex is formed with the specifically binding sequences, but not with the other members of the oligonucleotide mixture. The complex is then separated from uncomplexed oligonucleotides and the complexed members of the oligonucleotide mixture are recovered from the separated complex using the polymerase chain reaction. The recovered oligonucleotides may be sequenced, and successive rounds of selection using complexation, separation, amplification and recovery can be employed. The oligonucleotides can be used for therapeutic and diagnostic purposes and for generating secondary aptamers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 14 USPATFULL
ACCESSION NUMBER: 96:11063 USPATFULL
TITLE: Hybridoma and monoclonal antibody specific for human stem cell factor receptor and methods of use of the monoclonal antibody for detection of stem cell factor receptors
INVENTOR(S): Broudy, Virginia C., Seattle, WA, United States
Lin, Nancy, Seattle, WA, United States
PATENT ASSIGNEE(S): Board of Regeant of the University of Washington, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5489516		19960206
APPLICATION INFO.:	US 1993-11078		19930129 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-681245, filed on 5 Apr 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hutzell, Paula K.
LEGAL REPRESENTATIVE: Winter, Robert B., Nowak, Henry P.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 948
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to monoclonal antibodies specific for a cell receptor specific for human stem cell factor (hSCF) as well as compositions containing such monoclonal antibodies and uses of such monoclonal antibodies in assays for detection of stem cell factor receptors in stem cell populations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 14 MEDLINE
DUPLICATE 2
ACCESSION NUMBER: 97033967 MEDLINE
DOCUMENT NUMBER: 97033967 PubMed ID: 8879625
TITLE: Isolation of CD34+ hematopoietic progenitor cells in chronic myeloid leukemia by magnetic activated cell sorting (MACS).
AUTHOR: Martin-Henao G A; Ingles-Esteve J; Cancelas J A; Garcia J
CORPORATE SOURCE: Department of Cryobiology and Cell Therapy, Cancer Research Institute, Hospital Duran i Reynals, Barcelona, Spain.
SOURCE: BONE MARROW TRANSPLANTATION, (1996 Sep) 18 (3) 603-9. Journal code: 8702459. ISSN: 0268-3369.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199701
ENTRY DATE: Entered STN: 19970128
Last Updated on STN: 19970128
Entered Medline: 19970116
AB We have evaluated an easy and fast immunomagnetic method for positive selection of cells expressing the CD34 antigen from BM, peripheral blood (PB) and apheresis products (AP) of CML patients and healthy adults (HA) in order to further characterize them by immunophenotypic analysis. From an initial frequency of CD34+ cells in the original sample of 1.8 +/- 1.7%, CD34+ cells were rapidly and efficiently enriched up to 91.5 +/- 6.4% by high-gradient magnetic cell sorting (MACS) (yield 53 +/- 21%). A five-dimensional flow cytometric analysis of the immunomagnetic isolated CD34+ cells demonstrated little overlap between CD34+HLA-DRlo and CD34+CD38lo subpopulations in both BM-HA and in BM-CML. Only 16 and 6% of the CD34+HLA-DRlo and CD34+CD38lo cells respectively, showed lack of expression of both Ag (CD34+HLA-DRloCD38lo) in BM-CML samples. Between 60 and 70% of the CD34+ cells expressed the stem cell factor (SCF) receptor (c-KIT, CD117) and there were no differences between BM-HA and BM-CML patients. Moreover, more than 60% of the CD34+HLA-DRlo cells, co-expressed c-KIT. MACS-enriched BM-CD34+ cells showed normal hematopoietic colony formation in vitro in all the sources analyzed with a higher colony-forming efficiency than the unfractionated sample (MNC).

=> s tumor or cancer